However, without any further details on drug pricing from Democratic runners during the Tuesday debate, biotechnology and pharmaceutical stocks have been rebounding.
“The issue was a no-show,” Asthika Goonewardene, an analyst at Bloomberg Intelligence, said after the debate. “Absent new political proposals or price-gouging revelations, the sector may be past the worst of political ‘headline risks.”’
Market Vectors Pharmaceutical ETF
For more information on the pharma sector, visit our pharmaceuticals category.
Max Chen contributed to this article.